463 patents
Page 2 of 24
Utility
Biomarkers for Cancer Immunotherapy Outcomes
7 Dec 23
Provided herein, inter alia, are improved methods and systems of determining immunotherapy response in subjects prior and during treatment.
Andrea BILD, Jason I. GRIFFITHS
Filed: 30 May 23
Utility
Recombinant adeno-associated vectors for targeted treatment
5 Dec 23
Novel adeno-associated virus (AAV) vectors in nucleotide and amino acid forms and uses thereof are provided.
Saswati Chatterjee, Laura Jane Smith, Kamehameha Wong
Filed: 11 Feb 20
Utility
Methods of quantifying methylglyoxal-induced nucleic acid adducts
5 Dec 23
Methods of quantifying a N2-(1-carboxyethyl)-2′-deoxyguanosine (CEdG) and N2-(1-carboxyethyl)-guanosine (CEG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of metabolic disorders or complications associated therewith, including diabetes, its associated complications, and cancer.
Timothy W. Synold, John Termini, Sarah Shuck
Filed: 31 Jul 20
Utility
Vaccination of Hematopoietic Stem Cell Donors with Cytomegalovirus Triplex Composition
30 Nov 23
Disclosed is a method of treating or preventing a CMV infection in a recipient of a hematopoietic cell transplant (HCT).
Don J. DIAMOND, Corinna LA ROSA
Filed: 15 Oct 21
Utility
TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF IL13Ralpha2 POSITIVE MALIGNANCIES
23 Nov 23
Chimeric antigen receptor molecules that include a variant IL-13.
Christine E. Brown, Lawrence Stern, Xin Yang, K. Christopher Garcia, Ignacio Moraga Gonzalez
Filed: 19 Jan 21
Utility
Dual-targeting Chimeric Antigen Receptor Modified T Cells Comprising IL-13 and Chlorotoxin for Cancer Treatment
23 Nov 23
Chimeric antigen receptors having a chlorotoxin domain and an IL-13 are described.
Christine E. Brown, Dongrui Wang, Michael Barish, Stephen J. Forman
Filed: 11 Mar 21
Utility
Engineered T Cells for Expression of Chimeric Anitgen Receptors
16 Nov 23
Disclosed herein, inter alia, are methods of making and using engineered T cells useful for expressing a chimeric antigen receptor (CAR) targeted to a cell surface protein (e.g., a CAR targeted to IL13Rα2, which is highly expressed on glioblastoma cells).
Christine E. Brown, Dongrui Wang, Jeremy Rich, Qi Xie, Briana Prager
Filed: 23 Nov 21
Utility
Ex Vivo Expansion of Regulatory T Cells for Suppression of Graft Versus Host Disease
2 Nov 23
Provided herein, inter alia, are methods and compositions for treating or preventing graft-versus-host disease.
Fouad Kandeel
Filed: 15 Sep 21
Utility
Programming of Regulatory T Cells by Extracellular Vesicles
2 Nov 23
Provided herein, inter alia, are compositions and methods for reprogramming immune cells for treating or preventing immune disorders.
Fouad Kandeel
Filed: 15 Sep 21
Utility
Chimeric Antigen Receptors Targeted to Psca
2 Nov 23
Chimeric transmembrane immunoreceptors (CAR) targeted to PSCA are described.
Saul J. Priceman, Christine E. Brown, Stephen J. Forman
Filed: 17 Aug 22
Utility
Methods of using anti-MIR126 compounds
31 Oct 23
Provided herein are, inter alia, methods of treating red blood cell disorders and cancer using anti-miR126 compounds.
Guido Marcucci, Bin Zhang, Ya-Huei Kuo, Marcin Tomasz Kortylewski
Filed: 5 Mar 20
Utility
Compositions and Uses of CD45 Targeted Chimeric Antigen Receptor Modified T Cells
26 Oct 23
Immune cells, including T cells, expressing a chimeric antigen receptor targeted to CD45 are described.
Zhiqiang Wang, Christine E. Brown, Stephen J. Forman
Filed: 20 Aug 21
Utility
Methods for Intracellular Delivery and Enhanced Gene Targeting
26 Oct 23
Disclosed herein are methods and compositions for enhancing gene targeting.
Daniela CASTANOTTO, Cy STEIN, Xiaowei ZHANG
Filed: 21 Mar 23
Utility
ANTI-CD5 Antibody Compositions and Uses Thereof
26 Oct 23
Provided herein are, inter alia, antibodies (e.g., humanized antibodies, monoclonal antibodies) and antibody compositions (e.g., chimeric antigen receptors, bispecific antibodies) that are capable of binding CD5.
Hua YU, Chunyan ZHANG
Filed: 20 Aug 21
Utility
Compounds and Compositions Including Phosphorothioated Oligodeoxynucleotide, and Methods of Use Thereof
26 Oct 23
The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.
Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Guido Marcucci, Bin Zhang, Ya-Huei Kuo
Filed: 8 Feb 23
Utility
SMC1A Antibodies and Uses Thereof
26 Oct 23
Provided herein are, inter alia, antibodies capable of binding Structural Maintenance of Chromosome-1 (SMC1).
Sushma YADAV, Arthur RIGGS, David HORNE, John C. WILLIAMS
Filed: 14 May 21
Utility
Synthetic Modified Vaccinia Ankara (Smva) Based Coronavirus Vaccines
12 Oct 23
Disclosed are synthetic modified vaccinia ankara (MVA)-based vaccines for preventing or treating coronavirus infections and methods of producing the vaccines.
Don J. DIAMOND, Felix WUSSOW, Flavia CHIUPPESI
Filed: 17 May 21
Utility
Antisense Rna for Treatment of Sars-associated Coronavirus
12 Oct 23
Provided herein are, inter alia, nucleic acids (e.g., siRNA), lipid nanoparticles comprising nucleic acids, pharmaceutical compositions comprising nucleic acids, pharmaceutical compositions comprising lipid nanoparticles, and methods of treating COV-ID-19, SARS viruses, and Middle Eastern respiratory syndrome.
Kevin Morris, Tristan Scott, Roslyn Ray, Galina Shevchenko, Denis O'Meally
Filed: 23 Mar 21
Utility
DNA2 inhibitors for cancer treatment
10 Oct 23
Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.
Binghui Shen, Judith Campbell, Li Zheng, Hongzhi Li, David Horne, Jun Xie, Kenneth Karanja
Filed: 29 Oct 21
Utility
Compositions and methods for mitochondrial genome editing
10 Oct 23
Compositions and methods for mitochondria genome editing are provided.
John Burnett, Anh Pham
Filed: 9 Jun 17